It should be mentioned that 40% of our patients had NAFLD, which might influence the results slightly since NAFLD promotes STAT3 in tumor cells mediated through effector and helper T cells which might promote cancer initiation. The gene discussed is STAT3; the disease is metabolic dysfunction-associated steatotic liver disease.